Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

Highlight

– Twenty-four-week tapering of abrocitinib is feasible and effective in moderate-to-severe atopic dermatitis patients who have responded adequately.
– Dose reduction and interval extension tapering strategies both maintain high nonrelapse rates, with dose reduction showing fewer strategy switches due to disease fluctuation.
– Successful tapering reduces cumulative drug dose substantially, translating into significant cost savings.
– The study supports personalized abrocitinib tapering to reduce treatment burden while maintaining disease control.

Study Background

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus, eczematous lesions, and a relapsing course. Moderate-to-severe cases markedly impair quality of life and often require long-term systemic immunomodulatory therapy. Janus kinase (JAK) inhibitors such as abrocitinib have emerged as efficacious oral treatments, offering rapid and significant improvement for patients inadequately controlled with topical therapies.

Despite promising efficacy, the long-term management of moderate-to-severe AD remains challenging, especially balancing sustained disease control with minimizing side effects, treatment burden, and costs. Tapering systemic therapies after achieving clinical response is a common clinical goal to reduce medication exposure. However, evidence regarding the feasibility and optimal regimen of JAK inhibitor tapering is sparse, and there are no head-to-head real-world comparisons of different tapering strategies.

Study Design

Deng et al. conducted a retrospective single-center study involving 78 moderate-to-severe AD patients who had achieved an adequate clinical response with abrocitinib therapy. Patients underwent a 24-week tapering period, implemented either by dose reduction or by extending the dosing interval. The study aimed to assess the feasibility, efficacy, safety, and economic impact of these two tapering regimens in a real-world clinical context.

Key eligibility criteria included confirmed moderate-to-severe AD, documented adequate response to abrocitinib prior to tapering, and attendance at regular clinical follow-up visits. The primary endpoint was the successful tapering without relapse. Secondary measures included relapse rates at 12 and 24 weeks, treatment strategy-switch rates due to disease fluctuation, cumulative abrocitinib dose, and cost analysis.

Key Findings

Among 78 patients, 36 underwent dose reduction, and 42 had interval extension. Successful tapering was achieved in 76 patients (97.4%), indicating high feasibility. Nonrelapse rates were 97.4% at 12 weeks and 91.0% at 24 weeks overall. The tapering strategies differed in treatment consistency: patients in the interval extension group experienced a significantly higher rate of strategy switches due to disease fluctuation (28.6% vs. 8.3%, P = .041) compared to dose reduction group.

Reduction of the cumulative drug dose was considerable with tapering, with a mean consumption of 6908 mg in tapering groups compared with 16,800 mg projected in standard continuous dosing. Cost savings correlated accordingly, showing ¥2016.7 versus ¥4916.2 in projected standard treatment, yielding a total average saving of ¥ 2899.5 over 24 weeks.

Safety outcomes were not extensively detailed in the publication but no unexpected adverse events or safety concerns were reported, suggesting tapering did not compromise patient safety.

Expert Commentary

This study provides practical real-world insights into managing moderate-to-severe AD with abrocitinib tapering. The high success rate supports gradual dose de-escalation in patients with stable disease, potentially mitigating risks of overtreatment and reducing healthcare costs. The difference between tapering by dose reduction versus extending dosing intervals highlights the importance of individualized treatment plans, as interval extension may predispose some patients to fluctuations requiring regimen adjustments.

Limitations include the retrospective, single-center design, relatively small sample size, and short follow-up duration of 24 weeks. While these results are promising, prospective controlled studies with longer follow-up are warranted to confirm durability of remission and safety profile of tapering regimens.

Conclusion

Abrocitinib tapering over 24 weeks in well-responding moderate-to-severe AD patients is both feasible and safe, enabling significant reduction in drug exposure without compromising disease control. Dose reduction tapering appears preferable to interval extension due to lower rates of disease fluctuation and strategy changes. This approach offers a meaningful opportunity to optimize long-term treatment, improve patient quality of life, and reduce economic burden. Future research should explore patient-specific predictors of tapering success and establish evidence-based tapering protocols in AD therapeutic guidelines.

Funding and ClinicalTrials.gov

The original study was conducted without specified external funding sources. ClinicalTrials.gov registration was not indicated in the retrospective analysis.

References

1. Deng S, He Y, Wang H, Chen Q, Gao C, Song Z. Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison. J Am Acad Dermatol. 2026 Jul 9. PMID: 42423580.
2. Silverberg JI, Guttman-Yassky E, Nemoto O, et al. Abrocitinib for the treatment of moderate-to-severe atopic dermatitis: Results from the JADE clinical trial program. J Allergy Clin Immunol. 2021;147(6):2214–2223.
3. Furue M, Ito T. Novel therapies for atopic dermatitis targeting the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway: Current status and future prospect. J Allergy Clin Immunol. 2022;149(6):2150–2162.